Amylin: Physiology and What Research Reports

What Amylin Is

Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino-acid peptide hormone. A comprehensive pharmacological review described amylin as a beta-cell hormone co-secreted with insulin that contributes to the control of nutrient intake and glucose appearance in the blood (PMID 26071095). A later historical and translational overview traced amylin from its identification in pancreatic islet deposits through to its characterisation as a physiological hormone with therapeutic interest (PMID 41708975).

Because amylin is released from the same secretory granules as insulin, the literature commonly frames it as a partner hormone rather than an independent system: reviews reported that amylin and insulin act on different aspects of the same post-meal problem, insulin on glucose disposal and amylin on the rate at which nutrients arrive (PMID 26071095).

Where Amylin Is Produced

The primary source described in the literature is the pancreatic islet beta cell (PMID 26071095). Amylin expression has also been examined outside the pancreas: one study reported detection of amylin protein in the rat brain and in Neuro-2a cells, indicating that the peptide's expression is not limited to islet tissue (PMID 35457166).

What the Literature Says Amylin Does

Reviews of amylin physiology described a cluster of related actions that together reduce the speed and size of a nutrient load:

• Satiation. Researchers described amylin as a meal-ending (satiation) signal acting through the hindbrain (PMID 26071095).
• Gastric emptying and glucagon. A 2025 endocrinology review summarised amylin's effects on gastric emptying and glucagon secretion as central to its glucose-regulating profile (PMID 40360789).
• Energy expenditure. An experimental study reported that both central and peripheral administration of amylin induced energy expenditure in anesthetized rats (PMID 18346817).
• Body-weight relevance. Reviews framed amylin as a candidate signal in overweight, obesity and diabetes mellitus research (PMID 40360789).

Receptors: calcitonin receptor plus RAMPs

Amylin does not have a single dedicated gene-encoded receptor. Structural work reported that the amylin receptor phenotype arises when the calcitonin receptor associates with receptor activity-modifying proteins (RAMPs), and the study provided a structural basis for how that pairing produces amylin selectivity (PMID 35324283). This receptor architecture is one reason amylin pharmacology overlaps with calcitonin pharmacology in the reviews (PMID 26071095).

Amylin Brain Circuitry

A dedicated review of amylin brain circuitry described the area postrema and connected hindbrain nuclei as principal sites of amylin action, with onward projections that integrate amylin signalling into wider feeding circuits (PMID 32634450). Beyond the hindbrain, one rodent study reported that amylin receptor activation in the ventral tegmental area reduced motivated ingestive behavior, implicating reward-related circuitry rather than only homeostatic pathways (PMID 28552704).

Aggregation, Islet Amyloid and Neurodegeneration Research

Human amylin is aggregation-prone, and the peptide's name comes from the amyloid deposits found in islets. Reviews discussed this aggregation behaviour alongside amylin's hormonal role (PMID 26071095). An in vitro screening study reported that benzbromarone, quercetin and folic acid inhibited amylin aggregation, illustrating how small molecules have been used as experimental probes of the aggregation process (PMID 27322259). A separate commentary asked whether amylin signalling in diabetes and Alzheimer's disease should be read as therapy or pathology, reflecting the unresolved tension between amylin's hormonal actions and its amyloid-forming chemistry (PMID 31511851).

How Amylin Is Measured and Studied

The verified literature shows several distinct research approaches:

The recombinant work matters methodologically: a 2024 study described the construction and identification of a breast bioreactor for the human-derived hypoglycemic protein amylin, one route researchers have explored for producing the peptide for study (PMID 38398700).

Unexpected Directions in the Literature

Not all amylin research is metabolic. One 2025 study reported that amylin inhibited gastric cancer progression by targeting CCN1 and affecting the PI3K/AKT signalling pathway, an oncology-adjacent line of investigation distinct from the hormone's feeding and glucose roles (PMID 40165038).

Why Amylin Comes Up in Peptide Discussions

Readers most often meet the term amylin through metabolic-medicine coverage, because reviews have described amylin-based agents as an emerging pharmacological class for overweight, obesity and diabetes mellitus (PMID 40360789). A 2026 overview positioned this translational interest as the latest chapter in a longer story that began with amylin physiology (PMID 41708975). Understanding the underlying biology — a beta-cell peptide acting at calcitonin receptor–RAMP complexes in the hindbrain (PMID 35324283) — is what separates the physiology from marketing language about any particular product.

Tolerability and Safety Signals: What Studies Report

The verified papers on this page are predominantly physiology studies, structural work, in vitro assays and narrative reviews rather than tolerability trials, so they do not provide a catalogue of adverse events. Reviews discussed amylin's therapeutic opportunities together with the translational challenges of the peptide class (PMID 40360789), and one commentary explicitly raised the question of whether amylin signalling represents therapy or pathology given its amyloid-forming behaviour (PMID 31511851). Several of the physiological findings summarised above were reported in anesthetized or freely feeding rodents (PMID 18346817), and animal findings do not transfer automatically to humans. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision.

Key Takeaways

1. Amylin is a 37-amino-acid beta-cell peptide co-secreted with insulin (PMID 26071095).
2. Its receptors are calcitonin receptor–RAMP complexes, as shown structurally (PMID 35324283).
3. Reviews described actions on satiation, gastric emptying and glucagon (PMID 40360789).
4. Hindbrain and midbrain circuits have both been implicated in amylin's effects on intake (PMID 32634450, PMID 28552704).
5. Human amylin's aggregation chemistry keeps it relevant to amyloid research as well as metabolism (PMID 27322259).

References

• Amylin: Pharmacology, Physiology, and Clinical Potential (Pharmacological Reviews, 2015)
• The story of amylin: from physiology to therapy (Nature Metabolism, 2026)
• A structural basis for amylin receptor phenotype (Science, 2022)
• Amylin brain circuitry (Peptides, 2020)
• Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus (Nature Reviews Endocrinology, 2025)
• Benzbromarone, Quercetin, and Folic Acid Inhibit Amylin Aggregation (International Journal of Molecular Sciences, 2016)
• Amylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology? (Journal of Neurology & Neuromedicine, 2019)
• Amylin inhibits gastric cancer progression by targeting CCN1 and affecting the PI3K/AKT signalling pathway (Annals of Medicine, 2025)
• Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior (Neuropharmacology, 2017)
• Amylin Protein Expression in the Rat Brain and Neuro-2a Cells (International Journal of Molecular Sciences, 2022)
• Construction and Identification of a Breast Bioreactor for Human-Derived Hypoglycemic Protein Amylin (Life, 2024)
• Central and peripheral administration of amylin induces energy expenditure in anesthetized rats (Peptides, 2008)